A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome
METABOLIC SYNDROME, HYPERTENSION, PRE-HYPERTENSION
About this trial
This is an interventional prevention trial for METABOLIC SYNDROME focused on measuring METABOLIC SYNDROME, VALSARTAN, HYDROCHLOROTHIAZIDE, HYPERTENSION,
Eligibility Criteria
Inclusion Criteria: Waist circumference: males > 40", females > 35 " MSSBP ≥ 130 mmHg but ≤ 160 mmHg and a MSDBP ≥ 85 mmHg but ≤ 100 mmHg At least one of the following criteria: - Fasting plasma glucose between 5.9 and 6.9 mmol/L; - Serum triglycerides > 150 mg/dL; - LDL Cholesterol: - < 40 mg/dL males; - < 50 mg/dL females Exclusion Criteria: MSSBP> 180 mmHg or MSDBP > 110 mmHg Inability to discontinue all prior antihypertensives for a period of 4 weeks. History of diabetes History of stroke, transient ischemic attack or myocardial infarction. Significant weight change > 10 lbs during screening period Patients taking a diuretic for 3 months prior to screening. Other protocol-defined exclusion criteria may apply.
Sites / Locations
- Novartis Pharmaceuticals